Profile data is unavailable for this security.
About the company
Nova Mentis Life Science Corp. is a Canadian biotechnology company. The Company is engaged in developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders. The Company has orphan drug designation in both the United States and European Union for the use of psilocybin in the treatment of fragile X syndrome (FXS). Its focus is to diagnose and treat debilitating chronic conditions that have unmet medical needs, such as autism spectrum disorder (ASD) and FXS. Its core scientific focus is on chronic neuroinflammatory conditions, which fall under three categories: neurodevelopmental, neurometabolic, and neurodegenerative. The Company operates in one segment, being research and development of psilocybin, and in one geographic area, being Canada, through its wholly owned subsidiaries, Nova Mentis Biotech Corp., and SwabAi Diagnostics Inc.
- Revenue in CAD (TTM)0.00
- Net income in CAD-628.58k
- Incorporated2004
- Employees--
- LocationNova Mentis Life Science Corp700-838 West Hasting StreetVANCOUVER V6C 0A6CanadaCAN
- Phone+1 (778) 819-0244
- Fax+1 (778) 819-0244
- Websitehttps://www.novamentis.ca/